novel fibrinolytic enzyme produced by bacillus sp. capable of dissolving the clots of pa6 fibrin

摘要

the therapeutic approaches used today in response to vascular diseases include nonpharmacologic treatments (surgery, nutrition, pharmacology and therapeutics). these are essentially the antithrombotic agents and thrombolytic agents.the limitations of these traditional treatments have motivated the search for new drugs acting at different levels of the pathways of coagulation and fibrinolysis. new drugs of natural or synthetic origin have been developed in order to improve current treatments (choussat and montalescot, 1999).the present invention describes a novel fibrinolytic enzyme of pharmacological interest produced by the newly isolated strain of bacillus sp. 137 in the laboratory of enzyme engineering and microbiology (lgem), from the ground to a detergent plant.the enzyme of the invention has a main function to the destruction of fibrin clots under physiological conditions of ph, temperature and ion composition (ph 7.4; degree 2,68mm 136.9 mm nacl, kci, and 1.47 mm kh2po4, 8.1 mm na2hpo4). the enzyme of the invention is a serine protease with a molecular mass of 30 kda.the enzyme is active in a wide range of ph, with an optimum at ph 9.0 and recorded. the enzyme is active at temperatures ranging from 36 to 70 degrees c, with an optimum at only recorded after 10 min of incubation. however, the enzyme is very unstable at high temperature. the time of 1 / 2 to 60 degrees c is only 3 minutes, so that no loss of activity was observed after 1h incubation at 37oc.the study of the stability of the enzyme of the invention under physiological conditions of ph, temperature and ionic composition shows that it is very stable. the enzyme is more than 95% of its activity after 5 hours of incubation at 37oc.